Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 4 25 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 3 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 4 25 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 3 5 W ELECTROLYTES.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 3.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids (3.5% crystalline amino acids) and electrolytes for protein synthesis and maintenance of electrolyte balance in patients unable to meet nutritional needs enterally. The amino acids serve as substrates for protein synthesis, while electrolytes support cellular function and acid-base balance.
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
Intravenous: 500 mL to 2 L per day as part of total parenteral nutrition; infusion rate adjusted to meet nutritional requirements and clinical status.
None Documented
None Documented
Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
Amino acids: ~5–10 min for free amino acids (rapidly cleared from plasma); electrolytes: not applicable as they are distributed and eliminated via homeostasis; clinical context: infusion requires continuous monitoring due to rapid clearance.
The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Renal: 100% of infused amino acids and electrolytes are excreted renally as urea and electrolytes, respectively.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution